Heidi Sankala - Concepedia

Author

Heidi Sankala

Virginia Commonwealth University

Also Known As

H M Sankala, H. Sankala, Heidi M Sankala, Heidi M. Sankala, Heidi Sankala, Sankala, Heidi, Weir-Wiggins, Caryn

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Virginia Commonwealth University National Institutes of Health Virginia Commonwealth University Medical Center UNC Lineberger Comprehensive Cancer Center National Institute of Mental Health

About

Heidi Sankala is an author at Virginia Commonwealth University specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	498
2	Cell Biology	7	7	417
3	Health Sciences	2	2	62
4	Natural Sciences	2	2	238
5	Biochemistry	1	1	18

Heidi Sankala

Publications

Citations

H-Index

Page 1

	Year	Citations
SphK1 and SphK2, Sphingosine Kinase Isoenzymes with Opposing Functions in Sphingolipid Metabolism Michael Maceyka, Heidi Sankala, Nitai C. Hait, Journal of Biological Chemistry	2005	625
Sphingosine Kinase Type 2 Is a Putative BH3-only Protein That Induces Apoptosis Hong Liu, Rachelle E. Toman, Sravan K. Goparaju, Journal of Biological Chemistry	2003	357
Phosphorylation of Argonaute 2 at serine-387 facilitates its localization to processing bodies Yan Zeng, Heidi Sankala, Xiaoxiao Zhang, Biochemical Journal Molecular RegulationMolecular BiologyP38 MapkCellular PhysiologyProcessing Bodies	2008	220
Sphingosine kinase 1 is required for migration, proliferation and survival of MCF‐7 human breast cancer cells Sukumar Sarkar, Michael Maceyka, Nitai C. Hait, FEBS Letters	2005	202
Involvement of Sphingosine Kinase 2 in p53-Independent Induction of p21 by the Chemotherapeutic Drug Doxorubicin Heidi Sankala, Nitai C. Hait, Steven W. Paugh, Cancer Research	2007	156
Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors Puneet S. Jolly, Meryem Bektas, Kenneth R. Watterson, Blood	2005	58
p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity Catherine A. Vaughan, Shilpa Singh, Brad E. Windle, Archives of Biochemistry and Biophysics Transcriptional RegulationSignaling PathwayNf-κb2 PromoterMolecular PathwayCell Regulation	2011	58
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma Beata Holkova, Adriana Zingone, Maciej Kmieciak, Clinical Cancer Research	2015	48
The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Leanne Cartee, Zhiliang Wang, Roy H. Decker, PubMed Chemoprevention StrategyMitochondrial DysfunctionApoptosisRetinoblastoma ProteinCell Death	2001	46
Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance Heidi Sankala, Catherine A. Vaughan, Jing Wang, Archives of Biochemistry and Biophysics MitophagyMitochondrial FunctionMutant P53 ContributesMolecular BiologyMitochondrial Transport Protein	2011	44

Page 1